We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

72 hedge funds and large institutions have $88.9M invested in Aldeyra Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.28% less ownership

Funds ownership: 61.44%61.15% (-0.28%)

5% less funds holding

Funds holding: 7672 (-4)

12% less capital invested

Capital invested by funds: $101M → $88.9M (-$12.4M)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

63% less call options, than puts

Call options by funds: $76K | Put options by funds: $207K

Holders
72
Holders Change
-4
Holders Change %
-5.26%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
30
Reduced
19
Closed
10
Calls
$76K
Puts
$207K
Net Calls
-$131K
Net Calls Change
-$637K
Name Holding Trade Value Shares
Change
Change in
Stake
OAM
76
Oxford Asset Management
United Kingdom
-$106K -17,722 Closed
VF
77
Virtu Financial
New York
-$96K -15,932 Closed
EMG
78
Ellington Management Group
Connecticut
-$83K -13,800 Closed
LI
79
Leap Investments
Illinois
-$79K -13,200 Closed
CSS
80
Cubist Systematic Strategies
Connecticut
-$30K -5,072 Closed
Royal Bank of Canada
81
Royal Bank of Canada
Ontario, Canada
+$285 +53 +133%
FIA
82
FNY Investment Advisers
New York
+$538 +100 New

ALDX Hedge Fund Activity: Q3 2019 in Review

72 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2019, worth a combined $88.9M — down 12% from $101M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ALDX and 6 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 30 added.

The largest buyer was Millennium Management, adding an estimated $1.58M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.95M sold.

  • 72 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2019, down from 76 in Q2 2019.
  • Funds reported $88.9M of Aldeyra Therapeutics stock for Q3 2019, down 12% quarter-over-quarter.
  • 6 funds opened new Aldeyra Therapeutics positions in Q3 2019 and 10 closed out, a net change of -4 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2019 was Millennium Management, an estimated $1.58M added.
  • The largest Aldeyra Therapeutics seller in Q3 2019 was Point72 Asset Management, an estimated $1.95M sold.

Based on aggregated 13F filings for Q3 2019.